Key facts
- It has raised $106.0M; the latest was Early Stage VC ($58.0M) in Sep 2025.
- Notable investors include Pioneer Fund, Metaplanet Holdings, Founders Fund, Lux Capital, Day One Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for UntilLabs
- ·The full record, as it builds
Funding rounds
No funding rounds for UntilLabs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About UntilLabs
Operator of a research and development company intended to reversibly cryopreserve living tissue. The company's platform optimizes existing methods with traditional techniques from drug discovery and engineering work and develops novel molecular agents, perfusion and surgical protocols, and cooling and rewarming hardware to support reversible cryopreservation of biological systems, enabling transplant patients and surgeons to access the organs they need with technical competence in neuro cryopreservation.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2021
- Employees
- 37
- Website
- untillabs.com/
- Ownership
- Privately Held (backing)
UntilLabs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in UntilLabs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on UntilLabs in its N-PORT filings yet. We sweep new filings monthly.